secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039795
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q2 revenue $42M (+40% YoY); raises FY guidance to $191-197M
--------------------------------------------------------------------------

- Revenue $42.0M, up 40% YoY; gross margin 81.7% vs 82.3% last year.
- Net loss per share ($0.20) improved from ($0.31) YoY; adjusted EBITDA loss ($7.7M).
- FY2023 revenue guidance raised to $191-197M, representing 35-39% growth.
- Direct sales channel grew to 79% of sales; reached 200 quota-carrying sales reps.
- Completed acquisition of RedPoint Medical3D assets for patient-specific instrumentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/0000950170-23-039795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017023039795/tmci-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer